Stephanie Dudzinski MD, PhD

PGY-5 RadOnc resident at @MDAndersonNews 🩺 @VanderbiltMSTP/@VUMedicine '21⚕️@VandyBME Ph.D. '20 🔬@Duke BME '13🏀 Tennis Player🎾 Dancer💃 Foodie🍔

[Stephanie Dudzinski MD, PhD @StephDudzinski]

Over the moon that @sumeethj and I have matched at @MDAndersonNews and @BCMNeurosurgery for #radonc and #neurosurgery! We can't wait to start this new chapter of our lives with our family and incredible co-residents! #HoustonBound #Match2021

[Denise De la Cruz, Ed.D. @yogagirldd]

Happy #MatchDay2021‼️ Congrats and welcome 🙌🏼 @MDAndersonNews #radonc #residency #Classof2026 to the #workfam ☢️💛 @ChelseaPinnix @DrEmmaHolliday @StephDudzinski @RKouzyMD @adam_grippin @Enoch_Chang @cd_fuller @TaniguchiMD

[ACROresident @ACROresident]

🚨 RadOnc Residents & Attendings: Master TNM Staging with the official ACRO Anki Deck!700+ high-yield cards by disease site. Ideal for boards & rotations. Download: https://t.co/34DoO2nHxv ACRO → https://t.co/PDYXi1lYiQ #RadiationOncology #Anki

[Simran Polce, MD @SimranPolce]

Check out our new TNM Staging Anki Deck by the @ACROresident Group. Available for download under the Study Tools Section! Great for new residents and seniors.

https://t.co/YGUtBs42O8

@ACRORadOnc

[Amer. Radium Society @RadiumSociety]

Excited to share our latest publication!

These guidelines are designed to help radiation oncologists navigate clinical decision-making for patients with osteoarthritis— a progressive disease and the seventh leading cause of disability worldwide: https://t.co/zgh273nlvx

[Dr. Nina Niu Sanford @NiuSanford]

One of most interesting rectal ca studies at #ASCO26

P3 RCT in pMMR LARC: Node-sparing short-course RT + CAPOX + tislelizumab doubled pCR v conventional SCRT + CAPOX (61 v 29%)

Hypothesis = sparing elective node RT preserves antitumor immunity & improves PD1 response @OncoAlert

[Bobby Koneru, MD @KoneruMd]

We have never run a sham-controlled RCT for total knee replacement.

Not once. The most commonly performed orthopedic procedure in the United States, 700,000+ per year, has never been tested against placebo.

And yet when low-dose radiotherapy (LDRT) for knee OA is presented, the first objection is always: "Where's the sham-controlled data?"

That double standard is worth naming out loud.

Here is what LDRT actually has:

→ 2 positive sham controlled trials (Korean and Iranian)
→ A 292-patient prospective RCT (Russian) with 11 year follow-up
→ 4.5x difference in pain scores at 36 months across every domain (pain, stiffness, function, quality of life)
→ Plain-film radiography and MRI at 10 years showing a statistically significant reduction in marked progression
→ A 50-year European safety record with no meaningful toxicity

Here is what the treatments currently in OA guidelines have:

→ NSAIDs: known cardiovascular, renal, and GI harm at chronic doses
→ Glucosamine/chondroitin: failed large RCTs. Still in some guidelines.
→ Corticosteroid injections: emerging evidence of accelerated cartilage loss with repeat use
→ TKA: no sham trial. Ever.

If LDRT was a pill, it would be in every guideline.

The evidence bar being applied to LDRT is not being applied to anything else in this space.

The critics aren't wrong that we need a multicenter sham-controlled trial. We do. That's the ask.

But the argument that the current evidence is insufficient to justify treatment while we continue recommending interventions with weaker or more harmful evidence bases is not scientific rigor.

It is asymmetric scrutiny.

The field has been waiting decades for a non-surgical, disease-modifying treatment for OA. The data suggests we may have had it all along.

That conversation is overdue.

[Muhammad Ali @dr_alimuhammad]

Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.

https://t.co/07jeA1lQMb

[Matthias Guckenberger @Mat_Guc]

🚀 Virtual Grand Round in Radiation Oncology

Latest results of the EXTEND trial

🎤 Dr. Chad Tang

Addition of MTD to SoC for Oligometastatic Solid Tumors: Primary Analysis of EXTEND

📅 2. June 2026, 17:00–17:30 CEST
💻 Join us virtually here: https://t.co/8N7ysfum0s

[NRG Oncology @NRGonc]

1 WEEK AWAY - REGISTER for our NRG-GU015 "ARCHER" site webinar discussing the study assessments for the trial studying shorter duration RT for patients receiving chemotherapy for bladder cancer. This webinar will be June 9th at 1:00PM ET. Register at https://t.co/oiS6Z4RrP2

[Nancy Lee @imrtlee]

@KaramLab @DavidSherMD @EbnerMD @xrtGenomics Working really hard to get FDA approval so all can get FMISO PET. ❤️❤️❤️

[Amy Xu, MD PhD @AmyXuMDPhD]

✨ Inspiring to see @imrtlee representing ☢️ radiation oncology on the ASCO main stage.

Practice changing work reducing treatment toxicities and integrating radiographic biomarkers to personalize radiation

@MSK_RadOnc @MSKCancerCenter
#ASCO26 #RadOnc

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Today at #ASCO26: MSK radiation oncologist Dr. Nancy Lee (@imrtlee) shared long-term results showing that many patients with HPV-positive #oropharyngeal cancer were able to receive lower-dose radiation while maintaining durable outcomes and experiencing fewer side effects.

[Stephen Chun @StephenChunMD]

Do we need to do ADT for everyone w high risk prostate cancer? @NRGonc Podcast from #ASCO26 w @UTMDAnderson @krishnan_patel and @JeffersonUniv @APDicker on @Veracyte Decipher. @ASCO @RTOGFoundation @lauren_henke @felixfengmd @MaryFengMD

[Albert Koong, MD PhD @ACKoongMDPhD]

Amazing result for our patients. This is a new era for #PancreaticCancer. Congrats to @RevMedicines! #ASCO26

[Toni Choueiri, MD @DrChoueiri]

JUST In: TALAPRO-3 published in @NEJM

Adding #talazoparib to enzalutamide/ADT

=>3-year rPFS: 77% vs 56% in HRR-deficient metastatic prostate cancer !
Looking forward to full presentation by @neerajaiims who keeps changing SOC, one trial at a time.

@ASCO #ASCO26 @OncoAlert

[Stephen Chun @StephenChunMD]

Best of @NRGonc at #ASCO26. Listen to @NRGonc Podcast on @Veracyte Decipher for ADT in high-risk prostate cancer w @UTMDAnderson @krishnan_patel & @KimmelCancerCtr @JeffersonUniv @APDicker. Oncotype for prostate cancer! @lauren_henke @ACKoongMDPhD @PrajnanDasMD @RTOGFoundation

[Katy Beckermann @katy_beckermann]

A clarifying discussion from @brian_rini closing the GU session: living longer and living better, can we have both?

His synthesis across RAD-IO, RAMPART, and the decision regret work landed three points:
🔍 Chemoradiation plus durvalumab is tolerable with good short-term outcomes, but how it integrates with today's neo/adjuvant systemic regimens is still unsettled.
🔍 What CTLA-4 actually adds in adjuvant RCC remains unclear. RAMPART CTLA4/PD-L1 vs obs: DFS HR 0.65, OS HR 0.71, but a 32% bump in grade 3+ toxicity, and CheckMate 914 didn't deliver. We need RAMPART OS and non-clear cell data
🔬 Our QoL tools don't capture what patients actually live with. Patient-defined toxicity categories and regret scores belong in prospective trials, not as an afterthought.

The throughline: efficacy and toxicity have to be weighed in the same frame, and our current instruments only measure one side well.

Great discussion.
#RCC #BladderCancer #GUonc #ASCO26

[NRG Oncology @NRGonc]

NRG Oncology research presented at #ASCO26 starts today with two #HeadandNeckCancer trials highlighted during poster sessions. Check out ↪️NRG-HN006 with Dr. Stephen Lai and NRG-HN015 with @DrNabilSaba

[NRG Oncology @NRGonc]

The combined analysis of NRG #prostatecancer studies (NRG/RTOG 9202, 9413, 9902 & 0521) will be an oral presentation this afternoon by Dr. Krishnan Patel at #ASCO26. Immediately following the session at ASCO, catch our podcast episode recapping Dr. Patel's presentation.

[Stephanie Dudzinski MD, PhD @StephDudzinski]

Congrats to my amazing co-resident @Ansel_PhD!!!! We’re so lucky 🍀 to have you at @UTMDAnderson 👏💪🥳

[Emma B. Holliday MD @DrEmmaHolliday]

Have a little FOMO for missing ASCO this year- and sad to miss seeing our super star PGY3 @Ansel_PhD win his ASCO Young Investigator Award to study a bispecific HER2-CD47 antibody-drug conjugate to sensitize breast cancer to immunotherapy! 👏👏👏

[NRG Oncology @NRGonc]

PRESS RELEASE: Addition of Immunotherapy Continues to Show Survival Benefit in Prolonged Follow-up in NRG Oncology Trial for Primary Advanced Stage or Recurrent Endometrial Cancer - Read the Release: https://t.co/SdaHAszWe4